Compare PRSU & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSU | AVLN |
|---|---|---|
| Founded | 1926 | N/A |
| Country | United States | United States |
| Employees | 2100 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | 2026 |
| Metric | PRSU | AVLN |
|---|---|---|
| Price | $52.25 | $28.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $31.67 | N/A |
| AVG Volume (30 Days) | 301.2K | ★ 413.8K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.85 | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | $3.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.92 | $24.90 |
| 52 Week High | $56.52 | $33.32 |
| Indicator | PRSU | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.02 | 41.88 |
| Support Level | $51.19 | $27.22 |
| Resistance Level | $56.52 | $29.59 |
| Average True Range (ATR) | 1.70 | 1.94 |
| MACD | -0.54 | 0.21 |
| Stochastic Oscillator | 36.09 | 62.25 |
Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, Iceland and Costa Rica. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.